ClinicalTrials.gg
Active, not recruitingNCT07000474METRADUpdated Jun 3, 2025

Multiparametric Characterization of Colorectal Cancers (METRAD)

An observational study in Colo-rectal Cancer, sponsored by University Hospital, Brest. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by University Hospital, Brest · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 213 studies in Colonic Neoplasms with a site in France — 49 open to participants now, 66 under way, 13 of them phase 3. Colonic Neoplasms · France.

Planned enrollment
29th of 55
200 · median 220
Started
2025
with 8 others
Observational
55 of 213
14 open now
Primary completion
2026-12
later than 27 of 65 live
Registered
198th of 213
by date

Among the 213 studies in Colonic Neoplasms with a site in France, this one is the 29th largest by planned enrollment of the 55 observational ones that give a count, is one of 9 that started in 2025, is one of 55 observational ones, reaches primary completion later than 27 of the 65 other live ones, and was the 198th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

49 of the 213 studies in Colonic Neoplasms with a site in France are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies in Colonic Neoplasms with a site in France, or all of them as a file.
02

Study summary

The primary goal of this observational study is to assess the predictive value of a model developed through a multiparametric analysis of clinical images, histopathological data, CT scans, and molecular analysis. This analysis will be conducted on a retrospective cohort recruited at CHU Brest (training group). The model will then be validated using external cohorts from other centers (test group).

Read the detailed description

Around 20% of patients with colorectal cancer present with synchronous liver metastases at the time of diagnosis. In recent years, there has been increasing interest in the high-throughput extraction of quantitative data from medical images, a technique known as radiomics. Radiomic analysis can involve both qualitative and quantitative imaging parameters, which may be used independently or integrated into multiparametric prediction models.

This is a multicenter, retrospective study designed to investigate the demographic, clinical, and radiological features, treatment regimens, and outcomes of patients diagnosed with colorectal cancer. The study will involve the collection of anonymized clinical data, including age, sex, diagnosis date, treatment details, results from histopathological and genetic analyses, as well as pre- and post-treatment medical imaging typically performed as part of the management of colorectal cancer patients, along with survival and tumor recurrence data.

PRIMARY EVALUATION CRITERIA Prediction of recurrence/treatment response based on the radiomic model.

SECONDARY EVALUATION CRITERIA The impact of CT scan image acquisition and reconstruction parameters on the prognostic model.

03

Conditions studied

  • Colo-rectal Cancer

Keywords

  • colon cancer
  • rectal cancer
  • radiomics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of patients diagnosed with colorectal cancer (CRC) who are undergoing various stages of treatment and care. The cohort includes individuals who have been surgically treated for colorectal cancer, with or without additional therapies such as chemotherapy, radiotherapy, or immunotherapy. The population may also include patients who have undergone routine follow-up care after treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who have undergone surgery for colorectal cancer.

Exclusion criteria

Exclusion Criteria:

  • Patients under legal protection (guardianship, curatorship, etc.)
  • Refusal to participate (expressed opposition)
  • Individuals with conditions that could interfere with the study protocol or impact data integrity
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Brest

    Training cohort

    Other: Omics

  • External

    Validation cohort

    Other: Omics

Interventions

  • OtherOmics

    Multiparametric analysis of clinical images, histopathological images, CT scans, and molecular analysis.

06

What researchers measure

Primary outcomes

  1. survival predictive model

    The primary objective is to evaluate the predictive value of a model built through multiparametric analysis of clinical images, histopathological images, CT scans, and molecular analysis.

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — All collected data that underlie results in a publication

Supporting information: Study protocol

Time frame: Data will be available beginning three years and ending fifteen years following the final study report completion

Access criteria: Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
Jun 3, 2025
StartActual
Mar 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07000474
Responsible party
Sponsor
First posted
Jun 3, 2025
Start date
Mar 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion